Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …

Iron transport in the plasma is carried out by transferrin, which donates iron to cells through
its interaction with a specific membrane receptor, the transferrin receptor (TfR). A soluble …

Functional iron deficiency (FID) is a state in which there is insufficient iron incorporation into
erythroid precursors in the face of apparently adequate body iron stores, as defined by the …

BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …

R concentration. Abnormally high Epo levels have been reported in patients with aplastic
anemia, 11 and dramatic ECOMBINANT human erythropoietin (rHuEpo) became available …

ABSTRACT BIRKELAND, KI, J. STRAY-GUNDERSEN, P. HEMMERSBACH, J. HALLÉN, E.
HAUG, and R. BAHR. Effect of rhEPO administration on serum levels of sTfR and cycling …

Long‐term follow‐up data are presented on changes in peripheral blood counts and Hb
requirements of 11 patients with myelodysplastic syndromes (MDS) during iron chelation …

The athlete biological passport (ABP) was recently implemented in anti-doping work and is
based on the individual and longitudinal monitoring of haematological or urine markers …

Previous phase I-II clinical trials have shown that recombinant human erythropoietin
(rHuEpo) can ameliorate anemia in a portion of patients with multiple myeloma (MM) and …

Recombinant human erythropoietin (rHuEPO) is an effective treatment for the anaemia that
occurs secondary to various conditions, but its role in myelofibrosis with myeloid metaplasia …